Primecap Management Portfolio holdings
AUM
$126B
This Quarter Return
+8.27%
1 Year Return
+17.42%
3 Year Return
+102.42%
5 Year Return
+196.08%
10 Year Return
+554.06%
AUM
$144B
AUM Growth
+$144B
(+2%)
Cap. Flow
-$6.12B
Cap. Flow
% of AUM
-4.24%
Top 10 Holdings %
Top 10 Hldgs %
29.72%
Holding
347
New
10
Increased
59
Reduced
237
Closed
5
Top Buys
| 1 |
Bristol-Myers Squibb
BMY
|
$199M |
| 2 |
Intel
INTC
|
$175M |
| 3 |
Aurora
AUR
|
$116M |
| 4 |
Alibaba
BABA
|
$70.3M |
| 5 |
Pulmonx
LUNG
|
$63.2M |
Top Sells
| 1 |
Eli Lilly
LLY
|
$832M |
| 2 |
Tesla
TSLA
|
$502M |
| 3 |
Microsoft
MSFT
|
$331M |
| 4 |
Adobe
ADBE
|
$296M |
| 5 |
Qualcomm
QCOM
|
$274M |
Sector Composition
| 1 | Technology | 32.26% |
| 2 | Healthcare | 26% |
| 3 | Industrials | 11.45% |
| 4 | Consumer Discretionary | 10.84% |
| 5 | Financials | 10.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
226
American Homes 4 Rent
AMH
$13.3B
| $26.8M | 0.02% |
613,850
-13,000
| -2% | -$567K |
|
227
Kirby Corp
KEX
$5.42B
| $26.3M | 0.02% |
442,600
-4,200
| -0.9% | -$250K |
|
228
Dell
DELL
$82.6B
| $26.1M | 0.02% |
464,310
-4,260
| -0.9% | -$239K |
|
|
TPTX
229
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $25.9M | 0.02% |
544,010
+24,380
| +5% | +$1.16M |
|
230
Danaher
DHR
$147B
| $24.8M | 0.02% |
75,526
| – | – |
|
231
Gibraltar Industries
ROCK
$1.85B
| $24.7M | 0.02% |
371,100
| – | – |
|
232
GSK
GSK
$79.9B
| $24.3M | 0.02% |
551,400
| – | – |
|
233
Glaukos
GKOS
$5.5B
| $23.7M | 0.02% |
532,900
+32,700
| +7% | +$1.45M |
|
|
DOOR
234
DELISTED
MASONITE INTERNATIONAL CORP
DOOR
| $23.5M | 0.02% |
199,200
+2,000
| +1% | +$236K |
|
235
Rapid7
RPD
$1.34B
| $23.5M | 0.02% |
199,420
-5,680
| -3% | -$668K |
|
236
Leslie's
LESL
$61.7M
| $23.1M | 0.02% |
+976,800
| New | +$23.1M |
|
237
Enovis
ENOV
$1.77B
| $22.6M | 0.02% |
491,800
-97,800
| -17% | -$4.5M |
|
238
IMAX
IMAX
$1.54B
| $22.1M | 0.02% |
1,239,500
-99,900
| -7% | -$1.78M |
|
239
Altice USA
ATUS
$1.1B
| $21.8M | 0.02% |
1,346,300
+17,700
| +1% | +$286K |
|
|
GTM
240
ZoomInfo Technologies
GTM
$3.47B
| $20.3M | 0.01% |
315,969
-4,720
| -1% | -$303K |
|
241
GitLab
GTLB
$7.93B
| $20M | 0.01% |
+230,200
| New | +$20M |
|
242
Standard BioTools
LAB
$481M
| $20M | 0.01% |
5,093,403
-169,640
| -3% | -$665K |
|
243
Guardant Health
GH
$8.41B
| $19.7M | 0.01% |
196,652
| – | – |
|
244
Cameco
CCJ
$33.7B
| $19.4M | 0.01% |
890,400
+28,200
| +3% | +$615K |
|
245
Merck
MRK
$210B
| $18.7M | 0.01% |
243,700
-268,700
| -52% | -$20.6M |
|
246
Comscore
SCOR
$33.4M
| $18.2M | 0.01% |
5,447,627
-19,420
| -0.4% | -$64.9K |
|
247
Amicus Therapeutics
FOLD
$2.34B
| $17.6M | 0.01% |
1,528,000
-98,100
| -6% | -$1.13M |
|
248
BridgeBio Pharma
BBIO
$9.89B
| $17.5M | 0.01% |
1,050,740
+589,880
| +128% | +$9.84M |
|
|
GAN
249
DELISTED
GAN Ltd
GAN
| $17.4M | 0.01% |
1,890,785
| – | – |
|
250
Waters Corp
WAT
$18B
| $17.1M | 0.01% |
45,900
-300
| -0.6% | -$112K |
|